COLLABORATIVE DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND BETWEEN SYNTA PHARMACEUTICALS CORP. and SMITHKLINE BEECHAM CORPORATION (d/b/a GLAXOSMITHKLINE) October 8, 2007Collaborative Development, Commercialization and License Agreement • March 20th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
This COLLABORATIVE DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 8, 2007 (the “Execution Date”) and effective as of the Effective Date (as defined below), by and between Synta Pharmaceuticals Corp., a Delaware corporation with offices at 45 Hartwell Avenue, Lexington, Massachusetts 02421 (“SYNTA”), and SmithKline Beecham Corporation (doing business as GlaxoSmithKline), a Pennsylvania corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania 19101 (“GSK”). Each of GSK and SYNTA is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
Amendment No. 1 to Collaborative Development, Commercialization and License AgreementCollaborative Development, Commercialization and License Agreement • August 7th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
This amendment (the “Amendment”) dated June 27, 2008 is to the Collaborative Development, Commercialization and License Agreement dated October 8, 2007 between Synta Pharmaceuticals Corp., a Delaware corporation with offices at 45 Hartwell Ave., Lexington, Massachusetts 02421 (“Synta”), and SmithKline Beecham Corporation, a Pennsylvania corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania 19101 (“GSK”) (the “Agreement”).
